ADMA Biologics Inc (NASDAQ:ADMA) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund raised its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 12.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 274,419 shares of the biotechnology company's stock after purchasing an additional 30,400 shares during the quarter. New York State Common Retirement Fund owned 0.12% of ADMA Biologics worth $5,444,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Mark Sheptoff Financial Planning LLC acquired a new position in ADMA Biologics in the 4th quarter worth approximately $35,000. Tsfg LLC acquired a new position in shares of ADMA Biologics in the 1st quarter valued at about $51,000. Farther Finance Advisors LLC lifted its holdings in shares of ADMA Biologics by 1,149.1% in the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after buying an additional 2,505 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of ADMA Biologics in the 4th quarter valued at about $85,000. Finally, CIBC Private Wealth Group LLC lifted its holdings in shares of ADMA Biologics by 137.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after buying an additional 2,954 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial lifted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director directly owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the transaction, the director owned 478,194 shares in the company, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock worth $9,644,269 in the last ninety days. Insiders own 3.50% of the company's stock.

ADMA Biologics Price Performance

NASDAQ:ADMA traded up $0.11 during trading hours on Thursday, hitting $17.31. 1,817,498 shares of the stock were exchanged, compared to its average volume of 2,577,233. ADMA Biologics Inc has a 52-week low of $10.21 and a 52-week high of $25.67. The firm's fifty day moving average price is $19.01 and its 200 day moving average price is $18.73. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The company has a market cap of $4.13 billion, a P/E ratio of 20.36 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The firm had revenue of $114.80 million for the quarter, compared to analysts' expectations of $116.40 million. During the same quarter last year, the firm posted $0.08 earnings per share. ADMA Biologics's quarterly revenue was up 40.2% on a year-over-year basis. As a group, equities research analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.